410.337.4500

Current Clinical Trials

CLS1003-302 TOPAZ

A RANDOMIZED , MASKED, CONTROLLED TRIAL TO STUDY THE SAFETY AND EFFICACY OF SUPRACHOROIDAL CLS-TA IN COMBINATION WITH AN INTRAVITREAL ANTI-VEGF AGENT IN SUBJECTS WITH RETINAL VEIN OCCLUSION

ALLERGAN CEDAR-150998-005

SAFETY AND EFFICACY OF ABICIPAR PEGOL (AGN-150998-005) IN PATIENTS WITH NEOVASCULAR AGE- RELATED MACULAR DEGENERATION

 OCULAR PROTEOMICS- The Vitreous Proteome-20060001

NRI HAS BEEN CONDUCTING THE VITREOUS PROTEOMICS STUDY FOR OVER 10 YEARS. THE GOAL OF THIS STUDY IS TO LEARN ABOUT PROTEIN COMPONENTS OF THE EYE AND TO UNDERSTAND WHICH PROTEINS ARE ASSOCIATED WITH EACH RETINAL DISORDER.

Upcoming Trials 

NRI is in the process of enrolling in several new clinical trials.   Details will follow as the enrollment process is completed.

 

Recently Completed Trials 

GENENTECH (BOULEVARD)-BP29647

A MULTIPLE-CENTER, MULTIPLE-DOSE AND REGIMEN, RANDOMIZED, ACTIVE COMPARATOR CONTROLLED, DOUBLE-MASKED, PARALLEL GROUP, 36 WEEK STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF RO6867461 ADMINISTERED INTRAVITREALLY IN PATIENTS WITH CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION